MENU

Should you buy these healthcare shares?

There are very few areas of the market that I believe have such strong long-term growth prospects as the healthcare sector. This is largely down to the positive outlook for population growth and ageing populations.

The good news is that there are a great number of options to choose from in the sector. Are these three the ones to buy?

CSL Limited (ASX: CSL)

CSL is a global biotech star and arguably one of the highest quality companies on the Australian share market. Its shares have been on fire over the last 12 months thanks to a strong half-year result and positive guidance. While I would say its shares are close to being fully valued now, I still think it is worth buying its shares if you are prepared to hold onto them for the long-term. This is because of its pipeline of products and positive tailwinds for its core business.

Medical Developments International Ltd (ASX: MVP)

Medical Developments International is the growing healthcare company behind the popular Penthrox pain management product. The company has been busy successfully expanding the presence of Penthrox, also known as the green whistle, globally over the last couple of years. I expect this to underpin strong sales growth in the future, just as long as its recent road block in the U.S. market doesn’t derails things. Last month the U.S. Food and Drug Administration suspended the clinical program for Penthrox in the USA out of the blue. It will outline its issues and concerns in a letter to the company within the next couple of months. I would suggest investors wait to hear what these concerns are before investing.

ResMed Inc. (ASX: RMD)

Last week this sleep treatment company released its fourth quarter results and revealed a 13% increase in revenue to US$2.3 billion. ResMed’s bottom line growth was even more impressive, with income from operations growing 27% to US$542 million. Thanks to the positive outlook for the sleep treatment industry and its focus on the fast-growing cloud-connected medical device market, I feel confident there will be more of the same in FY 2019 and beyond.

Finally, here are three more top growth shares I would buy this month.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.